RELAY THERAPEUTICS INC (RLAY)

Company Profile

Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The company is headquartered in Cambridge, Massachusetts and currently employs 343 full-time employees. The company went IPO on 2020-07-16. The firm is focused on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The firm's Dynamo platform integrates an array of computational and experimental approaches designed to address drug-protein targets that have previously been intractable or inadequately addressed. The Company’s product candidates are RLY-4008, RLY-2608, and GDC-1971. RLY-4008 is an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), for patients with advanced or metastatic FGFR2-altered solid tumors. RLY-2608 is a pan-mutant (H1047X, E542X, and E545X) and isoform-selective phosphoinositide 3 kinase alpha (PI3Ka) inhibitor. GDC-1971 is an inhibitor of Src homology region 2 domain-containing phosphatase-2 (SHP2), as a monotherapy in patients with advanced or metastatic solid tumors.

Company Info

RELAY THERAPEUTICS INC

399 Binney Street, 2nd Floor

Cambridge MASSACHUSETTS 02139

P: 16173708837

CEO: Sanjiv K. Patel

Employees: 343

Website: https://relaytx.com/